1. Scrip
  2. >>Rare Diseases

More Positive Data For Recordati Cushing's Drug

Isturisa Could Become A Big Earner

 
• By Kevin Grogan

With Isturisa, licensed last year from Novartis, it seems as though the Italian drugmaker has got hold of a therapy that could become lucrative, as well as highly effective for Cushing's disease.

Cushings Syndrome
Cushing’s affects approximately one to two patients per million per year • Source: Shutterstock

Three months after US approval and a couple of weeks after the European launch, Recordati Industria Chimica & Farmaceutica SPA has announced positive results from a major late-stage study confirming the effectiveness of its Cushing's disease therapy, Isturisa.

The Italian group has reported top-line data from the Phase III LINC-4 study evaluating Isturisa (osilodrostat) in 73 patients with Cushing’s for whom pituitary surgery is not an option...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Rare Diseases

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Lundbeck Lifted By Leap In Migraine Therapy Sales

 
• By Kevin Grogan

Vyepti revenues rise by nearly 70% in the first quarter.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

More from Scrip

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.